Berberine — Isoquinoline alkaloid / AMPK activator
Berberine activates AMP-activated protein kinase (AMPK), a cellular energy sensor that mimics many effects of metformin and caloric restriction. AMPK activation: inhibits hepatic glucose production, increases insulin sensitivity, activates GLUT4 translocation, reduces lipogenesis, increases mitochondrial biogenesis. Additionally modulates gut microbiome (increases Akkermansia, Bifidobacterium), inhibits PCSK9 (LDL-lowering), downregulates NF-κB (anti-inflammatory), and has antimicrobial/anti-parasitic properties. Multiple meta-analyses demonstrate efficacy for T2DM, dyslipidemia, and PCOS comparable to first-line medications.
نظرة عامة
هذه الصفحة جزء من مكتبة المركّبات المُصنَّفة بالأدلة في Hormonaly. جميع الادعاءات السريرية مرتبطة بمصادر علمية مُحكَّمة عبر خط أنابيب التحقق المزدوج للاستشهادات.
فئة المركّب
Isoquinoline alkaloid / AMPK activator
آلية العمل
Berberine activates AMP-activated protein kinase (AMPK), a cellular energy sensor that mimics many effects of metformin and caloric restriction. AMPK activation: inhibits hepatic glucose production, increases insulin sensitivity, activates GLUT4 translocation, reduces lipogenesis, increases mitochondrial biogenesis. Additionally modulates gut microbiome (increases Akkermansia, Bifidobacterium), inhibits PCSK9 (LDL-lowering), downregulates NF-κB (anti-inflammatory), and has antimicrobial/anti-parasitic properties. Multiple meta-analyses demonstrate efficacy for T2DM, dyslipidemia, and PCOS comparable to first-line medications.
الوضع التنظيمي
OTC dietary supplement. Not FDA-approved for any indication. Prescription form not available in US. Approved as medication in China.
مستوى الأدلة
Moderate-High — multiple RCTs and meta-analyses for T2DM, dyslipidemia, PCOS. ADA position statement acknowledges berberine's glucose-lowering evidence but does not formally endorse as first-line.